FDA approval of mitapivat signals a shift in thalassaemia care, offering the first oral option to treat chronic anaemia. Firstpost brings out expert views on its benefits, limitations and access challenges.
For decades, thalassaemia management has remained tethered to the traditional pillars of regular blood transfusions and iron chelation. While these supportive measures are life-saving, they primarily address the symptoms of the disorder rather than the underlying biological mechanisms of chronic anaemia.
That paradigm is beginning to shift. With the US Food and Drug Administration approving mitapivat, the first oral therapy shown to improve red blood cell energy metabolism in thalassaemia, clinicians are rethinking how anaemia in these patients can be treated.
The approval has generated cautious optimism, particularly among adults with alpha- and beta-thalassaemia who remain dependent on transfusions or suffer long-term complications such as iron overload. As newer drug-based therapies emerge alongside gene-editing approaches, questions of effectiveness, safety, affordability and access have gained prominence, especially in high-burden countries such as India.
Firstpost spoke to Dr Upadhyay, Senior Consultant Hematologist and Oncologist at PSRI Hospital to understand what mitapivat means for thalassaemia care, its limitations and how it fits into the evolving treatment ecosystem.
Excerpts:
How does the FDA approval of mitapivat change current treatment options for anaemia in thalassaemia patients?
Dr Upadhyay: The FDA’s approval of mitapivat (marketed as Aqvesme for thalassaemia) represents a meaningful shift in treatment, particularly for adult patients with alpha- and beta-thalassaemia, including both transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) groups. This oral pyruvate kinase activator is the first therapy approved that directly targets red blood cell energy metabolism, improving haemoglobin levels and red cell survival rather than simply managing complications. Until now, treatment largely revolved around blood transfusions, iron chelation, and supportive care, all of which carry long-term risks. Mitapivat introduces a disease-modifying approach that can help reduce transfusion burden and improve quality of life in selected patients.
Based on available clinical data, what benefits and limitations of mitapivat should doctors clearly communicate to patients?
Dr Upadhyay: Clinical trials such as ENERGIZE and ENERGIZE-T have shown that mitapivat can produce meaningful increases in haemoglobin, often one gram per decilitre or more in a substantial proportion of adult patients, alongside improvements in fatigue and reduced transfusion needs for some. However, response rates vary, and not all patients benefit. Side effects including headache, nausea, insomnia, and potential liver-related risks have been reported, which is why the drug is regulated under a Risk Evaluation and Mitigation Strategy. Patients must understand both the potential benefits and the need for careful monitoring.
How relevant is this oral therapy for Indian thalassaemia patients?
Dr Upadhyay: India carries one of the world’s highest thalassaemia burdens, making an effective oral therapy potentially transformative. Reduced reliance on frequent transfusions could ease both medical and socioeconomic pressures. However, mitapivat is not yet approved in India, and access will depend on regulatory clearance, pricing, insurance coverage, and government support schemes. Cost remains a major concern, particularly for patients in rural and resource-limited settings, unless public health programmes actively facilitate access.
What do long-term studies suggest about safety and sustained effectiveness?
Dr Upadhyay: Long-term extension data from phase 2 studies indicate that some patients experience sustained haemoglobin improvement for several years, with consistent safety profiles and no unexpected long-term adverse signals. Still, broader real-world data will be essential to fully understand durability of benefit, rare side effects, and long-term outcomes in diverse populations.
How do gene-editing therapies compare with drug-based treatments like mitapivat?
Dr Upadhyay: Gene-editing therapies offer the possibility of long-term or curative outcomes, with promising rates of transfusion independence. However, they require complex procedures, specialised centres, intensive conditioning regimens, and come with high upfront costs and procedural risks. In contrast, drug-based therapies like mitapivat are non-curative but easier to administer, less invasive, and more scalable — though benefits may be partial and require lifelong use.
What role can government policy play in strengthening thalassaemia care in India?
Dr Upadhyay: Initiatives such as improved blood bank infrastructure, expanded screening programmes, financial assistance schemes, and progress on a National Blood Transfusion Bill can significantly strengthen comprehensive care. These measures help improve both short-term transfusion safety and long-term prevention, reducing complications and economic strain on families.
What emerging research could further reduce transfusion dependence?
Dr Upadhyay: Beyond mitapivat and luspatercept, ongoing research into gene therapy, gene editing, improved transplantation techniques, and better supportive care holds promise. Advances in donor availability and reduced-intensity conditioning may also make curative options accessible to more patients in the future.
End of Article